Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
$9.09
$9.06
$4.01
$9.10
$1.20B0.834.50 million shsN/A
GENPREX stock logo
GNPX
GENPREX
$0.28
-2.4%
$0.28
$0.20
$3.97
$9.42M-0.54.16 million shs152,198 shs
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
$0.00
$0.07
$6.56
$1.04M1.36315,915 shs1,648 shs
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
$2.36
+0.0%
$1.84
$1.07
$4.62
$246.72M0.36657,396 shs47,463 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
0.00%0.00%0.00%0.00%0.00%
GENPREX stock logo
GNPX
GENPREX
+2.76%+10.61%-8.95%+9.16%-84.36%
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
0.00%0.00%0.00%0.00%+6,463.64%
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
+2.61%+10.13%+33.33%+110.71%+38.01%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
GENPREX stock logo
GNPX
GENPREX
1.1224 of 5 stars
0.04.00.04.70.00.00.6
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
2.04 of 5 stars
3.63.00.00.02.40.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
0.00
N/AN/AN/A
GENPREX stock logo
GNPX
GENPREX
0.00
N/AN/AN/A
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
0.00
N/AN/AN/A
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
3.13
Buy$8.00238.84% Upside

Current Analyst Ratings Breakdown

Latest GNPX, CTIC, PRQR, and NMTR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$8.00
6/27/2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$8.00
5/13/2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$15.00 ➝ $9.00
4/29/2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$8.00
4/29/2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$5.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
$53M22.62N/AN/A($0.14) per share-64.93
GENPREX stock logo
GNPX
GENPREX
N/AN/AN/AN/A$0.15 per shareN/A
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
N/AN/AN/AN/A$0.19 per shareN/A
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
$20.46M12.14N/AN/A$0.91 per share2.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
-$92.99M-$0.58N/A26.74N/A-91.38%N/A-55.82%N/A
GENPREX stock logo
GNPX
GENPREX
-$21.11MN/A0.00N/AN/AN/A-664.65%-370.18%8/8/2025 (Estimated)
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
-$43.77M-$3.46N/AN/AN/AN/A-584.97%-159.45%N/A
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
-$30.04M-$0.35N/AN/AN/A-157.04%-53.49%-22.07%8/4/2025 (Estimated)

Latest GNPX, CTIC, PRQR, and NMTR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/8/2025N/A
GENPREX stock logo
GNPX
GENPREX
-$0.71N/AN/AN/AN/AN/A
5/12/2025Q1 2025
GENPREX stock logo
GNPX
GENPREX
-$0.82-$0.26+$0.56-$0.26N/AN/A
5/8/2025Q1 2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
-$0.09-$0.1082-$0.0182-$0.11$4.90 million$4.89 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
N/AN/AN/AN/AN/A
GENPREX stock logo
GNPX
GENPREX
N/AN/AN/AN/AN/A
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
N/AN/AN/AN/AN/A
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
N/A
1.27
1.26
GENPREX stock logo
GNPX
GENPREX
N/A
1.94
1.94
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
N/A
0.59
0.59
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
N/A
4.10
4.10

Institutional Ownership

CompanyInstitutional Ownership
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
91.45%
GENPREX stock logo
GNPX
GENPREX
14.05%
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
22.34%
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
32.65%

Insider Ownership

CompanyInsider Ownership
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
7.61%
GENPREX stock logo
GNPX
GENPREX
8.47%
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
2.40%
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
8.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
127131.88 million121.84 millionOptionable
GENPREX stock logo
GNPX
GENPREX
2033.15 million30.34 millionNo Data
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
2014.34 million13.99 millionNo Data
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
180105.21 million96.38 millionOptionable

Recent News About These Companies

ProQR Therapeutics N.V. (PRQR) - Yahoo Finance
ProQR: Q1 Earnings Snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTI BioPharma stock logo

CTI BioPharma NASDAQ:CTIC

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

GENPREX stock logo

GENPREX NASDAQ:GNPX

$0.28 -0.01 (-2.37%)
As of 10:55 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

9 Meters Biopharma stock logo

9 Meters Biopharma NASDAQ:NMTR

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

ProQR Therapeutics stock logo

ProQR Therapeutics NASDAQ:PRQR

$2.36 +0.00 (+0.04%)
As of 10:56 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.